Areas of Research: autoimmune diseases and autoantigens; immunopathogenesis of type 1 diabetes; humanized disease models; immunomodulatory therapies
Type 1 diabetes is an organ-specific autoimmune disease characterized by T cell-mediated destruction of the insulin-producing beta cells of the pancreatic islets. While insulin therapy allows for continuation of life, it neither cures the disease nor prevents its devastating complications. Studies utilizing the nonobese diabetic (NOD) mouse model of the disease have shown that T cells, recognizing autoantigenic peptides bound to major histocompatibility complex (MHC) molecules, are absolutely required for disease development. T cells specific for beta cell antigens can also be detected in the peripheral blood of type 1 diabetes patients. Our laboratory utilizes an extensive collection of mouse models to investigate the antigenic specificities, pathogenicity, and immunobiology of T cells in type 1 diabetes. These models are also being used to develop and optimize therapeutic strategies, and new, increasingly “humanized” mouse models are continually in development in our group. The goals of our work are to better understand the underlying immunopathogenesis of type 1 diabetes and to develop improved tools to monitor and manipulate pathogenic beta cell-specific T cells.
Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.